Intellia Therapeutics, Inc. ( NTLA) - Key Metrics
NTLA Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q2 | $0.06 | -$0.80 | -$1.50 | -$1.52 |
| 2026Q1 | $0.13 | -$0.81 | -$0.99 | -$0.99 |
| 2025Q4 | $0.21 | -$0.88 | -$0.64 | -$0.64 |
| 2025Q3 | $0.13 | -$0.92 | -$0.70 | -$0.70 |
| 2025Q2 | $0.14 | -$0.98 | -$0.96 | -$0.96 |
NTLA Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q2 | 0% | -5.29 |
| 2026Q1 | 0% | -3.96 |
| 2025Q4 | 0% | -2.71 |
| 2025Q3 | 0% | -4.69 |
| 2025Q2 | 0% | -2.39 |
NTLA
Price: $11.56
52 week price:
Earnings Per Share: -3.37 USD
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 1.1 million
Ebitda: -15.1 millionMarket Capitalization: 1.7 billion